NCT03422809

Brief Summary

The overall goal of this study is to examine the influence of the menstrual cycle on micronutrient concentrations and plasma volume in healthy, reproductive-age women with regular cycles. The investigators aim to quantify changes in micronutrient biomarker concentrations (zinc, copper, iron, and vitamin A) and plasma volume across the menstrual cycle in healthy women.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
47

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 16, 2018

Completed
1 day until next milestone

Study Start

First participant enrolled

January 17, 2018

Completed
20 days until next milestone

First Posted

Study publicly available on registry

February 6, 2018

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 20, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 20, 2018

Completed
Last Updated

February 1, 2019

Status Verified

January 1, 2019

Enrollment Period

10 months

First QC Date

January 16, 2018

Last Update Submit

January 30, 2019

Conditions

Keywords

Plasma volume, micronutrient, estrogen, progesterone

Outcome Measures

Primary Outcomes (4)

  • Change in serum zinc concentration across the menstrual cycle

    Difference in mean serum zinc concentrations measured at three time points (day \~2, day\~12 and day\~21) within a single menstrual cycle will be examined.

    ~3 weeks (~day 2 to day ~21 of a 28 day menstrual cycle)

  • Change in serum copper concentration across the menstrual cycle

    Difference in mean serum copper concentrations measured at three time points (day \~2, day\~12 and day\~21) within a single menstrual cycle will be examined.

    ~3 weeks (~day 2 to day ~21 of a 28 day menstrual cycle)

  • Change in serum retinol concentration across the menstrual cycle

    Difference in mean serum retinol concentrations measured at three time points (day \~2, day\~12 and day\~21) within a single menstrual cycle will be examined.

    ~3 weeks (~day 2 to day ~21 of a 28 day menstrual cycle)

  • Change in plasma volume across the menstrual cycle

    Difference in mean plasma volume measured at three time points (day \~2, day\~12 and day\~21) within a single menstrual cycle will be examined.

    ~3 weeks (~day 2 to day ~21 of a 28 day menstrual cycle)

Secondary Outcomes (2)

  • Change in serum ferritin concentration across the menstrual cycle

    ~3 weeks (~day 2 to day ~21 of a 28 day menstrual cycle)

  • Change in hemoglobin concentration across the menstrual cycle

    ~3 weeks (~day 2 to day ~21 of a 28 day menstrual cycle)

Eligibility Criteria

Age18 Years - 44 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsParticipant eligibility is based on biological description of gender identity.
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Eligible women in the State College area and surrounding towns within Centre County, Pennsylvania, United States.

You may qualify if:

  • Female
  • to 44 years of age
  • General good health (does not have a known, ongoing health condition/medical issue that requires regular monitoring by a doctor or regular visits to the hospital)
  • BMI 18.5-24.9 kg/m2
  • Regular menstrual cycle (26-35 days)
  • Non-smoker
  • Non-pregnant
  • If pregnant before, ≥12 months since last pregnancy

You may not qualify if:

  • Known allergy to shellfish or iodine
  • Blood pressure on the day of measurements is low or high (systolic blood pressure (SBP) \<90 or ≥130 mmHg and/or diastolic blood pressure (DBP) \<60 or ≥80 mmHg)
  • Currently has low or high blood pressure (SBP \<90 or ≥130 mmHg and/or DBP \<60 or ≥80 mmHg), self-reported
  • Current hypertension or previous hypertensive disorder in pregnancy (gestational hypertension or preeclampsia)
  • Taking regular medication(s) (physician's prescribed medications for a health condition)
  • Currently trying to conceive
  • Currently breastfeeding
  • Currently using hormonal birth control or used within last 3 months
  • Used depot medroxyprogesterone acetate (DMPA) in the past 12 months
  • Diagnosis of polycystic ovary syndrome

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Pennsylvania State University

State College, Pennsylvania, 16802, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma, serum and urine samples

Study Officials

  • Alison Gernand, PhD

    The Pennsylvania State University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Professor of Nutritional Sciences

Study Record Dates

First Submitted

January 16, 2018

First Posted

February 6, 2018

Study Start

January 17, 2018

Primary Completion

November 20, 2018

Study Completion

November 20, 2018

Last Updated

February 1, 2019

Record last verified: 2019-01

Data Sharing

IPD Sharing
Will not share

Locations